Keyword: Galena BioPharma

SEC hits out at paid-for bioanalysts, CEOs and firms, charges 27

The Securities and Exchange Commission (SEC) has charged 27 companies and individuals over allegations of fraudulent promotion of stocks, as it says it has uncovered a number of writers, sometimes paid by biotech CEOs and comms firms, dressing up unbiased reporting while secretly being paid to tout a company stock.

Galena plummets on Phase III trial halt

Galena Biopharma fell more than 80% in premarket trading on news that an Independent Data Monitoring Committee stopped a Phase III trial of its NeuVax in early stage breast cancer for futility.